TBC 3711
Alternative Names: TBC3711Latest Information Update: 24 Oct 2021
At a glance
- Originator Encysive Pharmaceuticals
- Class Anti-ischaemics; Heart failure therapies; Isoxazoles; Small molecules; Thiophenes
- Mechanism of Action Endothelin A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cardiovascular disorders; Resistant hypertension
Most Recent Events
- 11 Jun 2008 Encysive Pharmaceuticals has been acquired by Pfizer
- 21 Mar 2007 Phase-II clinical trials in Resistant hypertension in USA (PO)
- 12 Dec 2006 Phase-I clinical trials in Cardiovascular disorders in USA (PO)